ARIH2P1: Potential Drug Target for Cancer (G390844)

Target Name: ARIH2P1

NCBI ID: G390844

ARIH2P1

Other Name(s): Ariadne homolog 2 pseudogene 1 | ARIH2P | ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1

ARIH2P1: Potential Drug Target for Cancer

ARIH2P1, also known as Arih2p1, is a gene that has been identified in the database as a pseudogene, which means it is a non-functional DNA sequence that has no known function. However, recent studies have suggested that it may have a role in the development and progression of various diseases, including cancer.

One of the most promising aspects of ARIH2P1 is its potential as a drug target. Several studies have shown that inhibiting the activity of ARIH2P1 can lead to a reduction in the growth of cancer cells, and some even suggest that it may be a useful therapy for certain types of cancer.

One of the ways in which ARIH2P1 may be involved in cancer development is by regulating the activity of cell signaling pathways that are involved in the growth and proliferation of cancer cells. These pathways include the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation, and the TGF-β signaling pathway, which is involved in the regulation of cell growth and differentiation.

Research has shown that ARIH2P1 is involved in the regulation of the PI3K/Akt signaling pathway, and that its activity in this pathway may be important for the growth and survival of cancer cells. Several studies have shown that inhibiting the activity of ARIH2P1 can lead to a reduction in the growth of cancer cells, and that this effect is dose-dependent.

Another potential mechanism by which ARIH2P1 may be involved in cancer development is by regulating the activity of cell signaling pathways that are involved in the regulation of cell growth and differentiation. The TGF-β signaling pathway, which is involved in the regulation of cell growth and differentiation, has also been shown to be involved in the development of cancer.

Research has shown that ARIH2P1 is involved in the regulation of the TGF-β signaling pathway, and that its activity in this pathway may be important for the regulation of cell growth and differentiation. This suggests that ARIH2P1 may be a useful target for therapies that are aimed at inhibiting the growth and survival of cancer cells.

In addition to its potential role in the regulation of cell signaling pathways, ARIH2P1 has also been shown to be involved in the regulation of gene expression. This suggests that it may be involved in the development and progression of cancer by modulating the activity of genes that are involved in cancer development.

Overall, while more research is needed to fully understand the role of ARIH2P1 in cancer development and progression, it is clear that it is an important candidate as a drug target. Further studies are needed to determine the exact mechanisms by which ARIH2P1 is involved in cancer and to explore its potential as a therapy.

Protein Name: Ariadne RBR E3 Ubiquitin Protein Ligase 2 Pseudogene 1

The "ARIH2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARIH2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets